Multaq News and Research

RSS
Actavis’ net revenue increases 40% to $2.66B in Q1 2014

Actavis’ net revenue increases 40% to $2.66B in Q1 2014

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Sanofi, POZEN ink license agreement to commercialize PA8140 and PA32540 tablets in US

Lead investigator to discuss growing impact of AFib on US health care costs and resources

Lead investigator to discuss growing impact of AFib on US health care costs and resources

CCS presents new 2010 Atrial Fibrillation Guidelines

CCS presents new 2010 Atrial Fibrillation Guidelines

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Patient enrollment completed in Phase 2 clinical trial of orBec for prevention of acute GVHD

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Sanofi-aventis commences multinational Phase IIIb PALLAS trial of Multaq in permanent AF patients

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

Antiarrhythmic drug dronedarone less effective and causes fewer side effects

USPTO issues patent for Incisive Surgical's proprietary INSORB Absorbable Skin Stapling Technology

USPTO issues patent for Incisive Surgical's proprietary INSORB Absorbable Skin Stapling Technology

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Kun Run Biotechnology's fiscal 2009 fourth-quarter revenues decrease 19%

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

Silence Therapeutics, Dainippon Sumitomo Pharma announce expansion of siRNA delivery collaboration

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

NICE appraisal committee publishes preliminary recommendation of Multaq for AF

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

ARYx Therapeutics announces operating results for the third quarter of 2009

ARYx Therapeutics announces operating results for the third quarter of 2009

sanofi-aventis reports financial results for the third quarter of 2009

sanofi-aventis reports financial results for the third quarter of 2009

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

European CHMP recommends marketing approval for Sanofi-aventis' Multaq

Aryx Therapeutics reports Q2 2009 financials

Aryx Therapeutics reports Q2 2009 financials

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Multaq approved for atrial fibrillation by FDA

Multaq approved for atrial fibrillation by FDA

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation

FDA approves Multaq tablets (dronedarone) to treat atrial fibrillation